MedCity News
MARCH 10, 2024
Given the link established across studies between marketing practices and the opioid overdose crisis, a few strategic steps can form a path forward for clinicians and policymakers.
pharmaphorum
MARCH 10, 2024
The FDA has said it will seek the advice of independent advisors before it concludes its review of Eli Lilly’s amyloid-targeting Alzheimer’s disease therapy donanemab, delaying its review of the drug. Lilly said the US regulator “wants to further understand topics related to evaluating the safety and efficacy of donanemab,” which includes the safety and efficacy results of its pivotal TRAILBLAZER-ALZ 2 study.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MedCity News
MARCH 10, 2024
Health systems aren’t seeing a ton of ROI when it comes to their AI investments quite yet, as use of the technology is still in an iterative stage. However, Mount Sinai CEO Brendan Carr thinks that is likely to change in the next couple years.
Pharmacy Times
MARCH 10, 2024
In addition, the length of hospital admissions were greater in patients with hidradenitis suppurativa-associated cutaneous squamous cell carcinoma compared to other admissions.
MedCity News
MARCH 10, 2024
With its new partnerships, Wheel is able to connect its customers’ patients with mental health services through Talkspace, home delivery pharmacy services through Cost Plus Drugs and lab and diagnostic services through Health Gorilla.
PharmExec
MARCH 10, 2024
Sales and marketing effectiveness of speaker programs is often one of the least understood aspects in the industry. Yet, pharma brands spent over $12.5 billion in 2022 to engage and influence with HCP-to-HCP activities. CMS’s Open Payments data is an overlooked tool to get greater visibility and create more strategic opportunities—while also enriching compliance.
MedCity News
MARCH 10, 2024
As the healthcare industry grapples with various challenges, from workforce shortages to complex coding intricacies, embracing AI can empower revenue cycle professionals to envision a future with reduced denials, optimized revenue, and fortified financial health.
Expert insights. Personalized for you.
128 
Let's personalize your content